Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2003 2
2006 1
2007 1
2008 1
2009 2
2010 6
2011 2
2012 5
2013 3
2014 5
2015 5
2016 2
2017 3
2018 6
2019 3
2020 9
2021 4
2022 4
2023 2
Text availability
Article attribute
Article type
Publication date

Search Results

56 results
Results by year
Filters applied: . Clear all
Page 1
Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non-inferiority trial and meta-analysis.
Glasier AF, Cameron ST, Fine PM, Logan SJ, Casale W, Van Horn J, Sogor L, Blithe DL, Scherrer B, Mathe H, Jaspart A, Ulmann A, Gainer E. Glasier AF, et al. Lancet. 2010 Feb 13;375(9714):555-62. doi: 10.1016/S0140-6736(10)60101-8. Epub 2010 Jan 29. Lancet. 2010. PMID: 20116841 Clinical Trial.
FINDINGS: In the efficacy-evaluable population, 1696 women received emergency contraception within 72 h of sexual intercourse (ulipristal acetate, n=844; levonorgestrel, n=852). There were 15 pregnancies in the ulipristal acetate group (1.8%, 95% CI 1.0-3.0) and 22 …
FINDINGS: In the efficacy-evaluable population, 1696 women received emergency contraception within 72 h of sexual intercourse (ulipristal …
Ulipristal Acetate for Treatment of Premenstrual Dysphoric Disorder: A Proof-of-Concept Randomized Controlled Trial.
Comasco E, Kopp Kallner H, Bixo M, Hirschberg AL, Nyback S, de Grauw H, Epperson CN, Sundström-Poromaa I. Comasco E, et al. Am J Psychiatry. 2021 Mar 1;178(3):256-265. doi: 10.1176/appi.ajp.2020.20030286. Epub 2020 Dec 10. Am J Psychiatry. 2021. PMID: 33297719 Clinical Trial.
The authors investigated continuous treatment with a selective progesterone receptor modulator, ulipristal acetate (UPA), as a potential treatment for PMDD. METHODS: The authors conducted an investigator-initiated, multicenter, double-blind, randomized, parallel-group clin …
The authors investigated continuous treatment with a selective progesterone receptor modulator, ulipristal acetate (UPA), as a potent …
Evaluation of ovulation and safety outcomes in a multi-center randomized trial of three 84 day ulipristal acetate regimens.
Westhoff CL, Archer DF, Barnhart K, Darney P, Gilliam M, Jensen J, Nelson A, Teal S, Thomas M, Hu J, Brown J, Blithe DL. Westhoff CL, et al. Contraception. 2022 Aug;112:54-60. doi: 10.1016/j.contraception.2022.04.002. Epub 2022 Apr 14. Contraception. 2022. PMID: 35430238 Clinical Trial.
OBJECTIVES: To describe ovulation inhibition and safety of daily oral ulipristal acetate (UPA) over 84 days. STUDY DESIGN: This multi-center phase 1 and/or 2 trial randomized participants to use oral ulipristal 10 mg or 5 mg daily or a 3 cycle regimen of 5 mg for 24 …
OBJECTIVES: To describe ovulation inhibition and safety of daily oral ulipristal acetate (UPA) over 84 days. STUDY DESIGN: This multi …
The progesterone-receptor modulator, ulipristal acetate, drastically lowers breast cell proliferation.
Westhoff CL, Guo H, Wang Z, Hibshoosh H, Polaneczky M, Pike MC, Ha R. Westhoff CL, et al. Breast Cancer Res Treat. 2022 Apr;192(2):321-329. doi: 10.1007/s10549-021-06503-1. Epub 2022 Jan 11. Breast Cancer Res Treat. 2022. PMID: 35015210 Clinical Trial.
Median BPE scores decreased from 3 to 1 in the ulipristal group (p = 0.008) and did not decrease in the COC group. CONCLUSION: Ulipristal was associated with a major decrease in Ki67%+ and BPE. Ulipristal would warrant further investigation for breast cancer …
Median BPE scores decreased from 3 to 1 in the ulipristal group (p = 0.008) and did not decrease in the COC group. CONCLUSION: Uli …
Antiprogestins reduce epigenetic field cancerization in breast tissue of young healthy women.
Bartlett TE, Evans I, Jones A, Barrett JE, Haran S, Reisel D, Papaikonomou K, Jones L, Herzog C, Pashayan N, Simões BM, Clarke RB, Evans DG, Ghezelayagh TS, Ponandai-Srinivasan S, Boggavarapu NR, Lalitkumar PG, Howell SJ, Risques RA, Rådestad AF, Dubeau L, Gemzell-Danielsson K, Widschwendter M. Bartlett TE, et al. Genome Med. 2022 Jun 15;14(1):64. doi: 10.1186/s13073-022-01063-5. Genome Med. 2022. PMID: 35701800 Free PMC article. Clinical Trial.
These findings were validated by an alternate progesterone receptor antagonist, ulipristal acetate, which yielded similar results. Importantly, mifepristone reduced both the TP53 mutation frequency as well as the number of TP53 mutations in mitotic-age-responders. ...Clini …
These findings were validated by an alternate progesterone receptor antagonist, ulipristal acetate, which yielded similar results. Im …
Pharmacodynamics and pharmacokinetics of a copper intrauterine contraceptive system releasing ulipristal acetate: A randomized proof-of-concept study.
Brache V, Vieira CS, Plagianos M, Lansiaux M, Merkatz R, Sussman H, Cochon L, Tejada AS, Kumar N, Loeven D, Blithe DL, Aprem AS, Williams AR, Kannan A, Bagchi IC, Sitruk-Ware R. Brache V, et al. Contraception. 2021 Oct;104(4):327-336. doi: 10.1016/j.contraception.2021.06.010. Epub 2021 Jun 19. Contraception. 2021. PMID: 34157312 Free PMC article. Clinical Trial.
OBJECTIVES: To assess pharmacodynamic and pharmacokinetic outcomes of a novel copper (Cu) intrauterine system (IUS) releasing ulipristal acetate (UPA) in healthy women. STUDY DESIGN: In this single-blinded, randomized proof-of-concept study, ovulatory women received one of …
OBJECTIVES: To assess pharmacodynamic and pharmacokinetic outcomes of a novel copper (Cu) intrauterine system (IUS) releasing ulipristal …
Ulipristal acetate use in adenomyosis: A randomized controlled trial.
Capmas P, Brun JL, Legendre G, Koskas M, Merviel P, Fernandez H. Capmas P, et al. J Gynecol Obstet Hum Reprod. 2021 Jan;50(1):101978. doi: 10.1016/j.jogoh.2020.101978. Epub 2020 Nov 10. J Gynecol Obstet Hum Reprod. 2021. PMID: 33186772 Clinical Trial.
OBJECTIVE: To evaluate the effect of a 10 mg per day 12 week treatment of ulipristal acetate (UPA) on abnormal uterine bleeding due to adenomyosis. ...
OBJECTIVE: To evaluate the effect of a 10 mg per day 12 week treatment of ulipristal acetate (UPA) on abnormal uterine bleeding due t …
Ulipristal Acetate for Treatment of Uterine Leiomyomas: A Randomized Controlled Trial.
Liu JH, Soper D, Lukes A, Gee P, Kimble T, Kroll R, Mallick M, Chan A, Gillard P, Harrington A, Sniukiene V, Shulman LP. Liu JH, et al. Obstet Gynecol. 2018 Nov;132(5):1241-1251. doi: 10.1097/AOG.0000000000002942. Obstet Gynecol. 2018. PMID: 30303900 Clinical Trial.
METHODS: This phase 3, double-blind, double-dummy, placebo-controlled trial randomized premenopausal women (18-50 years) with uterine leiomyomas and abnormal uterine bleeding to once-daily 5 mg ulipristal, 10 mg ulipristal, or placebo in two 12-week treatment course …
METHODS: This phase 3, double-blind, double-dummy, placebo-controlled trial randomized premenopausal women (18-50 years) with uterine leiomy …
Ulipristal acetate versus gonadotropin-releasing hormone agonists prior to laparoscopic myomectomy (MYOMEX trial): Long term results of a double-blind randomized controlled trial.
De Milliano I, Middelkoop MA, Huirne JAF, Kwee J, Geomini PMAJ, Schoot BC, Van Baal M, Bosmans JE, Hehenkamp WJK. De Milliano I, et al. Eur J Obstet Gynecol Reprod Biol. 2020 Sep;252:256-264. doi: 10.1016/j.ejogrb.2020.06.035. Epub 2020 Jun 16. Eur J Obstet Gynecol Reprod Biol. 2020. PMID: 32634673 Clinical Trial.
OBJECTIVE: The aim of this study was to compare the effect of ulipristal acetate (UPA) and gonadotropin-releasing hormone agonists (GnRHa) before laparoscopic myomectomy on long term secondary outcomes of the MYOMEX-trial, regarding quality of life, ultrasound characterist …
OBJECTIVE: The aim of this study was to compare the effect of ulipristal acetate (UPA) and gonadotropin-releasing hormone agonists (G …
Ulipristal Acetate for Treatment of Symptomatic Uterine Leiomyomas: A Randomized Controlled Trial.
Simon JA, Catherino W, Segars JH, Blakesley RE, Chan A, Sniukiene V, Al-Hendy A. Simon JA, et al. Obstet Gynecol. 2018 Mar;131(3):431-439. doi: 10.1097/AOG.0000000000002462. Obstet Gynecol. 2018. PMID: 29420395 Free PMC article. Clinical Trial.
OBJECTIVE: To assess efficacy and tolerability of ulipristal acetate, a selective progesterone receptor modulator, for treatment of symptomatic uterine leiomyomas. ...Time to amenorrhea was shorter for both ulipristal doses compared with placebo (P<.001), and bot …
OBJECTIVE: To assess efficacy and tolerability of ulipristal acetate, a selective progesterone receptor modulator, for treatment of s …
56 results